Medication that has been a lifeline for patients with uncontrollable diabetes is now slowly shifting from injections to pills, a move that could fundamentally alter treatment for the disease – and who can access it.
This shift could also affect the treatment of obesity, a long misunderstood condition once associated with overeating and laziness, rather than the metabolic disorder it is now recognised as.
Recommended Stories
list of 4 items list 1 of 4 Can GLP-1 drugs like Ozempic cause vision loss? What we know about the risk
list 2 of 4 Sweet scoop: Ice-cream study points to potential sugar substitute
list 3 of 4 Food or medicine? The impossible choices facing Sudan’s chronically ill
list 4 of 4 With every rainfall, Gaza risks losing access to power and healthcare
end of list
GLP-1 (glucagon-like peptide-1) receptor agonists therapy isn’t new.…